金龙胶囊对肝癌切除后复发转移影响的初步临床观察

目的:观察金龙胶囊对肝切除术后肝癌肝内转移复发、机体细胞免疫的影响并评估其临床疗效。方法:将肝细胞癌122例随机分成治疗组与常规化疗对照组,观察血清中NK细胞和T细胞亚群的变化;检测血清中的MMP-9和AFP水平;术后1年内,每个月行B超检查1次,每3个月行增强CT1次,观察肿瘤有无复发及临床疗效并对生活质量进行评分。结果:术后肝癌切除联合金龙胶囊治疗组CD4 /CD8 和NK细胞水平高于对照组,P<0.05;治疗组血清AFP与对照组比较差异无统计学意义,但MMP-9水平明显低于对照组,P<0.05;治疗组术后半年影像学检查肿瘤复发率为37.7%(23/61),与对照组60.6%(37/61),比较差异有统计学意义,P<0.05。治疗组平均生存期、中位生存期较对照组明显延长,P=0.001;生活质量评分治疗组明显优于对照组,P<0.05。结论:肝癌切除术后联合金龙胶囊治疗能明显降低MMP-9的水平,有效抑制残肝术后肝内转移的发生;对患者的细胞免疫功能影响小,有利于患者术后免疫功能的及时恢复;同时可提高临床疗效及患者术后生活质量及生存期,对于肝细胞肝癌的预后具有重要的临床价值。

Effect of jinlong capsule combined with hepatectomy on HCC intrahepatic metastasis

OBJECTIVE:To investigate the therapeutic effectiveness of jinlong capsule on intrahepatic metastasis and cellular immunity after hepatectomy in hepatocellular carcinoma(HCC) in human.METHODS:A total of 122 cases with resectable hepatocellular carcinoma were collected and divided into two groups randomly:a jinlong capsule combined with hepatectomy group(treatment group) and control group.The serous values of T lymphocyte phenotypes,NK cells,AFP and MMP-9 were measured respectively;B ultrasonic and CT were used to detected for intrahepatic dissemination and recurrence of HCC after the hepatectomy,with B ultrasonic test every month and CT test every three months,respectively.The therapeutic effectiveness was evaluated by UICC standard,the quality of life was evaluated by Karnofsky method,and the survival of patients was evaluated by Kaplan-Meier.RESULTS:After the treatment,the serous levels of CD4 /CD8 and NK cells in the control group were much lower than those in the treatment group,P<0.05.There was no difference of the serous levels of AFP between the two groups after the operation,but MMP-9 levels in the treatment group were much lower than those in the control group,P<0.05.The recurrence rate of intrahepatic dissemination in the treatment group(37.7%,23/61) was much lower than that in the control group(60.6%,37/61),P<0.05.The survival time(mean days or median days) in the treatment group were longer than those in the control group(P=0.001),and the effective rate and quality of life of the treatment group were significantly better than those of the control group,P<0.05.CONCLUSION:Jinlong capsule combined with hepatectomy for HCC patients has no effect on cellular immunity,can decrease the serous level of MMP-9,inhibit intrahepatic dissemination,and improve the effectiv rate,survival time and the quality of life of patients with HCC.